Colorectal Cancer Trial, Recruiting (NCT06734156)

Colorectal Cancer Trial, Recruiting NCT06734156 Sponsor: Gulbenkian Institute for Molecular Medicine Condition: Colorectal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06734156 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Colorectal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are willing and able to give written agreement to take part in the study
People who live in Portugal
People who are between 40 and 74 years old
People who have recently been diagnosed with colorectal cancer (bowel cancer) and have not yet started any treatment for it

Who may not be able to join:

People who are under 40 years old or 75 years old and above
People who are not able to give written agreement to take part
People who are not willing to provide stool (poo) samples
People who have previously had or are currently receiving treatment for colorectal cancer (bowel cancer)
People who have a parent, sibling, or child who has been diagnosed with colorectal cancer (bowel cancer)
People who have previously been diagnosed with inflammatory bowel disease (such as ulcerative colitis, Crohn's disease, or indeterminate colitis), irritable bowel syndrome, or repeated infections with a bacteria called Clostridioides difficile
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ana S Almeida, PhD, Gulbenkian Institute for Molecular Medicine

Phone: +351 217999411

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06734156

Sponsor: Gulbenkian Institute for Molecular Medicine

Phase: Not Applicable

Status: Recruiting

Condition: Colorectal Cancer

Trial contact: +351 217999411

More information: https://clinicaltrials.gov/study/NCT06734156

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are willing and able to give written agreement to take part in the study
People who live in Portugal
People who are between 40 and 74 years old
People who have recently been diagnosed with colorectal cancer (bowel cancer) and have not yet started any treatment for it

Who may not be able to join:

People who are under 40 years old or 75 years old and above
People who are not able to give written agreement to take part
People who are not willing to provide stool (poo) samples
People who have previously had or are currently receiving treatment for colorectal cancer (bowel cancer)
People who have a parent, sibling, or child who has been diagnosed with colorectal cancer (bowel cancer)
People who have previously been diagnosed with inflammatory bowel disease (such as ulcerative colitis, Crohn's disease, or indeterminate colitis), irritable bowel syndrome, or repeated infections with a bacteria called Clostridioides difficile
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Gulbenkian Institute for Molecular Medicine

Registry

ClinicalTrials.gov

Start date

2 March 2026

Est. completion

2 December 2026

Where this trial is recruiting

🇵🇹 Portugal

Primary endpoints

Microbiome biomarkers associated with CRC.; Microbiome biomarkers associated with EoCRC.; Correlation between microbiome biomarkers and overall survival and disease-free survival.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov